TG THERAPEUTICS INC. - COMMON STOCK

TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2024 Net Revenue and 2025 Anticipated Development Milestones

14 1 2025 07:00:00 提供 Nasdaq GlobeNewswire

TG Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

09 1 2025 07:30:00 提供 Nasdaq GlobeNewswire

TG Therapeutics to Participate in the Evercore HealthCONx Conference

29 11 2024 08:00:00 提供 Nasdaq GlobeNewswire

NetDania - New 12 months High: TG THERAPEUTICS INC. - COMMON STOCK

25 11 2024 09:47:54 提供 NetDania Notify

TG Therapeutics Ranked Number One Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™

21 11 2024 06:00:00 提供 Nasdaq GlobeNewswire

NetDania - New 12 months High: TG THERAPEUTICS INC. - COMMON STOCK

14 11 2024 09:55:54 提供 NetDania Notify

NetDania - New 12 months High: TG THERAPEUTICS INC. - COMMON STOCK

13 11 2024 11:43:19 提供 NetDania Notify

NetDania - New 12 months High: TG THERAPEUTICS INC. - COMMON STOCK

12 11 2024 09:50:33 提供 NetDania Notify

NetDania - New 12 months High: TG THERAPEUTICS INC. - COMMON STOCK

11 11 2024 09:45:41 提供 NetDania Notify

NetDania - New 12 months High: TG THERAPEUTICS INC. - COMMON STOCK

08 11 2024 14:45:51 提供 NetDania Notify

NetDania - New 12 months High: TG THERAPEUTICS INC. - COMMON STOCK

07 11 2024 10:01:11 提供 NetDania Notify

NetDania - New 12 months High: TG THERAPEUTICS INC. - COMMON STOCK

06 11 2024 09:45:06 提供 NetDania Notify

TG Therapeutics Reports Third Quarter 2024 Financial Results and Raises BRIUMVI® (ublituximab-xiiy) Full Year Revenue Guidance

04 11 2024 07:00:00 提供 Nasdaq GlobeNewswire

NetDania - New 12 months High: TG THERAPEUTICS INC. - COMMON STOCK

01 11 2024 11:54:23 提供 NetDania Notify

TG Therapeutics to Host Conference Call on Third Quarter 2024 Financial Results and Business Update

01 11 2024 08:06:02 提供 Nasdaq GlobeNewswire

NetDania - New 12 months High: TG THERAPEUTICS INC. - COMMON STOCK

18 9 2024 09:45:02 提供 NetDania Notify

New BRIUMVI® (ublituximab-xiiy) Data from the ENHANCE Phase 3b Study Show Rapid 30-Minute Infusions are Well Tolerated in Patients with Relapsing Forms of Multiple Sclerosis

18 9 2024 07:15:00 提供 Nasdaq GlobeNewswire

New Data for BRIUMVI® (ublituximab-xiiy) Demonstrate that 92% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 5 Years of Treatment

18 9 2024 07:00:03 提供 Nasdaq GlobeNewswire

NetDania - New 12 months High: TG THERAPEUTICS INC. - COMMON STOCK

17 9 2024 12:04:03 提供 NetDania Notify

NetDania - New 12 months High: TG THERAPEUTICS INC. - COMMON STOCK

16 9 2024 14:44:05 提供 NetDania Notify